http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28481133

Outgoing Links

Predicate Object
contentType Journal Article|Multicenter Study|Randomized Controlled Trial
issn 0300-0605
1473-2300
issueIdentifier 12
pageRange 3000605211062770-
publicationName The Journal of international medical research
startingPage 3000605211062770
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_44098326dffafda1298f34497c8369ad
bibliographicCitation Suzuki S, Yoshihisa A, Yokokawa T, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Tsuda A, Tsuda T, Ishibashi T, Konno I, Yamaguchi O, Machii H, Nozaki N, Niizeki T, Miyamoto T, Takeishi Y; multicenter randomized trial investigators. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. 2021 Dec;49(12):3000605211062770. PMID: 34914568; PMCID: PMC8689623.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5beb9cd4207033a863c76aac9f1557a7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d0c55629fb8192dcfecd9646bd2d8b9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d369282fc18d5092a4a83a65ec42feb6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f341cdfbcbc03afe580554c81dc1522
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3548-1604
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54cb82765d5a9742c0003fcb68cf04f0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_261af8e513b53ce26446067e7e5b8dc4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16818fc5979aaabfb013f651e03926bb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7fd007f5f268340ecde588cd7b5e0d7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_252c90154f58d6e07b466ca603d495e1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a54ac1eeaba0635fb6b366ef40985ef
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b0f93c7c35796142809df5908cc5642
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e971fb50af1ff268b5dfcbade4110039
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4a471029be1f2d84f20e7648de2f384
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb5d7d0c0afffecc970a4670c07ec5cd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e1b4a24525f780022de9bc387ff9c16
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee52638ccd2d2a71c037d00e098fd854
date 202112
identifier https://pubmed.ncbi.nlm.nih.gov/34914568
https://pubmed.ncbi.nlm.nih.gov/PMC8689623
https://doi.org/10.1177/03000605211062770
isPartOf https://portal.issn.org/resource/ISSN/0300-0605
https://portal.issn.org/resource/ISSN/1473-2300
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3376
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
discusses http://id.nlm.nih.gov/mesh/M0224789
http://id.nlm.nih.gov/mesh/M0022340
http://id.nlm.nih.gov/mesh/M0000745
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D006333Q000188
http://id.nlm.nih.gov/mesh/D033461Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000493Q000627
http://id.nlm.nih.gov/mesh/D014527
http://id.nlm.nih.gov/mesh/D000069465Q000627
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ecc266125c8edd0cd09261012266c141
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7922
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7181
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1044
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135401907
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10751
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135440064
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134018
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1175

Total number of triples: 55.